Several clinical features of prostate cancer, such as tumor cell differentiation or GS and serum PSA, are used in routine clinical practice to stratify men into low-, intermediate-, and high-risk groups for tumor recurrence after local therapy. This evidence concerns the gene KLK3 and prostate cancer.